Skip to main content
NCBI home page
Springer logoLink to Springer
. 2023 Jan 8;43(4):667–676. doi: 10.1007/s00296-022-05258-2

Rheumatoid arthritis study of the Egyptian College of Rheumatology (ECR): nationwide presentation and worldwide stance

Tamer A Gheita 1,✉, Hala A Raafat 1, Samah A El-Bakry 2, Ahmed Elsaman 3, Hanan M El-Saadany 4, Nevin Hammam 5, Iman I El-Gazzar 1, Nermeen Samy 2, Nora Y Elsaid 1, Suzan S Al-Adle 1, Samar Tharwat 6, Amira M Ibrahim 7, Samar M Fawzy 1, Nahla N Eesa 1, Rawhya El Shereef 8, Faten Ismail 8, Mervat I Abd Elazeem 9, Enas A Abdelaleem 9, Amany El-Bahnasawy 10, Zahraa I Selim 5, Nada M Gamal 5, Maha Nassr 11, Samah I Nasef 12, Abdel Hafeez Moshrif 13, Shereen Elwan 4, Yousra H Abdel-Fattah 14, Marwa A Amer 14, Doaa Mosad 10, Eman F Mohamed 15, Dina F El-Essawi 16, Hanan Taha 17, Mohamed N Salem 17, Rasha M Fawzy 18, Maha E Ibrahim 12, Asmaa Khalifa 3, Nouran M Abaza 19, Ahmed M Abdalla 20, Amany R El-Najjar 21, Noha A Azab 1, Hanan M Fathi 11, Khaled El-Hadidi 1, Tahsin El-Hadidi 22; The Egyptian College of Rheumatology (ECR) Rheumatoid Arthritis Study Group
PMCID: PMC9995404  PMID: 36617362

Abstract

To depict the spectrum of rheumatoid arthritis (RA) in Egypt in relation to other universal studies to provide broad-based characteristics to this particular population. This work included 10,364 adult RA patients from 26 specialized Egyptian rheumatology centers representing 22 major cities all over the country. The demographic and clinical features as well as therapeutic data were assessed. The mean age of the patients was 44.8 ± 11.7 years, disease duration 6.4 ± 6 years, and age at onset 38.4 ± 11.6 years; 209 (2%) were juvenile-onset. They were 8750 females and 1614 males (F:M 5.4:1). 8% were diabetic and 11.5% hypertensive. Their disease activity score (DAS28) was 4.4 ± 1.4 and health assessment questionnaire (HAQ) 0.95 ± 0.64. The rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) were positive in 73.7% and 66.7% respectively. Methotrexate was the most used treatment (78%) followed by hydroxychloroquine (73.7%) and steroids (71.3%). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt (p < 0.0001), while the highest DAS28 was reported in Canal cities and Sinai (p < 0.0001). The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai (p = 0.001). Biologic therapy intake was higher in Lower Egypt followed by the Capital (p < 0.0001). The spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.

Keywords: Rheumatoid arthritis, Age at onset, Gender, Biologics, Egypt, Multicenter

Introduction

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease primarily affecting small synovial joints usually symmetrically. Symptoms for more than 6 months establish the diagnosis of RA [1]. An intricate network of cytokines and cells trigger synovial cell proliferation and cause damage to both cartilage and bone [2].

Alone the laboratory test for RA cannot confirm a diagnosis that is commonly challenging. A complete clinical approach is necessary to diagnose and avoid debilitating joint damage [1]. Yet, auto-antibodies signify a hallmark of RA, with the rheumatoid factor (RF) and anti-cyclic citrullinated (anti-CCP) peptides being the most acknowledged. Seropositive patients present a certain disease course. With the recent improvements in diagnosis and the discovery of new autoantibodies, the group of seronegative patients is persistently shrinking [3]. Using applicable disease activity measures can help in clinical practice to take on treat-to-target strategies in RA patients [4]. There has been a rising importance for the early and demanding diagnosis and treatment of RA with the goal of reducing disability and mortality [5].

To improve the clinical outcome in RA, various therapeutic approaches are required [1], although current management recommendations may still support a 'one-size-fits-all' treatment strategy [6]. Early treatment with disease-modifying anti-rheumatic drugs (DMARDs) is standard, yet many patients progress to disability with substantial morbidity over time [1]. The arrival of biologics has changed the treatment of RA due to their remarkable impact on disease manifestations and their ability to diminish joint damage [5]. With the development of biologics and Janus kinase (JAK) inhibitors [2], these agents are being used by a rising number of patients including those with a mild disease. However, cost and safety issues remain key determinant [2, 5]. Personalized medicine is necessary to select special treatment strategies for certain clinical or molecular phenotypes of patients [6] and key factors of RA disease such as epidemiology, clinical presentations and treatment options should be presented.

In the milieu of the restricted information on the epidemiology and treatment patterns of RA across Egypt, the aim of the present study was to present the spectrum of RA in Egypt and compare it to other studies from around the world to provide broad-based characteristics to this particular population.

Patients and methods

Study population and design

This cross-sectional study included a large cohort of 10,364 adult RA patients (new and existing cases) fulfilling the American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification criteria [7] that were recruited from 26 specialized rheumatology departments and centers representing 22 major governorates across the country by members of the Egyptian College of Rheumatology (ECR) during the period from September 2018 till December 2021. Any patients with another rheumatic disease or below the age of 18 were excluded. The patients’ in the corresponding university-teaching hospitals provided informed consents to participate and the study was approved by the local ethics committee, in accordance to the 1964 Helsinki declaration and its later amendments.

Measures and outcomes

Patients were subjected to full history taking and clinical examination. Juvenile-onset RA (JoRA) cases were considered for those who developed the disease before the age of 18 years. It is noteworthy that co-morbidities or manifestations relied on the records of the files. Presence of rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) were determined. The use of medications to treat RA was described. Disease activity score (DAS28) [8] and health assessment questionnaire (HAQ) [9] were assessed.

Statistical analysis

Data were collected on a standardized data sheet and stored in an electronic database. Data missing completely at random (MCAR) as for the RF, anti-CCP and anti-nuclear antibody (ANA) positivity was handled by running a complete-case analysis (CCA), where all persons with missing values were excluded from the analysis of this test and imputation was not used. Statistical Package for Social Sciences (SPSS) version 25 was used. Variables were presented as frequencies and percentages or mean and standard deviation. A comparison was done using Chi-square test, Mann Whitney U tests or analysis of variance (ANOVA). P value < 0.05 was considered significant.

Results

The study included 10,364 RA patients recruited from 22 governorates across Egypt. Their mean age was 44.8 ± 11.7 years. They were 8750 females and 1614 males (F:M 5.4:1). Characteristics of the patients and gender differences are presented in Table 1. 209 (2%) were Jo-RA. Steroids were received by 71.3% of the patients. DMARDs were received in the following descending frequency: methotrexate (MTX) (78%), hydroxychloroquine (HCQ) (73.6%), leflunomide (LFN) (54.8%), sulfasalazine (SAZ)(37.2%), cyclophosphamide (CYC) (2.4%), azathioprine (AZA)(2%), cyclosporine A (CSA)(0.5%) and mycophenolate mofetil (MMF)(0.46%). Steroids and DMARDs received were comparable between genders except for HCQ (male: 77.6% vs females 73%; p = 0.002). Biologic therapy was received by 11.6% with a significantly higher frequency by males vs females (15.7% vs 10.9%, p = 0.001). Biologic therapies received were etanercept (30.4%), adalimumab (18.4%), golimumab (14%), rituximab (7.9%), infliximab (3.3%), tofacitinib (1.6%), certolizumab (1%), upadacitinib (0.8%), baricitinib (0.39%), abatacept (0.39%) and undefined (17.8%). Patients also received low dose aspirin (4.6%), colchicine (1.3%) and oral anticoagulants (1.1%).

Table 1.

Characteristics of the rheumatoid arthritis patients and gender differences: demographic features, co-morbidities, manifestations, laboratory investigations, functional status and disease activity

Parameter n (%) or mean ± SD Rheumatoid arthritis patients p
All
(n = 10,364)		 Females
(n = 8750)		 Males
(n = 1614)
Age (years) 44.8 ± 11.7 44.4 ± 11.6 47.1 ± 12.1  < 0.0001
Female:Male 5.4:1 – – –
Disease duration (years) 6.4 ± 6.03 6.4 ± 6 6.5 ± 6.4 0.66
Age at onset (years) 38.4 ± 11.6 38 ± 11.4 40.7 ± 12.3  < 0.0001
BMI 28.5 ± 5.3 28.5 ± 5.3 28.6 ± 5.5 0.89
Smoking 849 (8.2) 213 (2.4) 636 (39.4)  < 0.0001
Married 9458 (91.1) 7993 (91.3) 1465 (90.8) 0.64
Comorbidity
 Diabetes mellitus 833 (8) 689 (7.8) 144 (8.9) 0.22
 Hypertension 1194 (11.5) 995 (11.4) 199 (12.3) 0.36
 HCV 88 (0.85) 72 (0.82) 16 (1) 0.55
 Bronchial asthma 68 (0.66) 63 (0.72) 5 (0.31) 0.01
 Thyroid dysfunction 185 (1.8) 178 (2) 7 (0.43)  < 0.0001
Family hx RA (1st degree) 155 (1.5) 136 (1.6) 19 (1.2)  < 0.0001
Manifestations
 Rheumatoid nodules 413 (4) 339 (3.9) 74 (4.6) 0.16
 Ocular 1086 (10.5) 904 (10.3) 182 (11.3) 0.37
 Sjögren’s syndrome 980 (9.5) 870 (9.9) 110 (6.8)  < 0.0001
 CNS 703 (6.8) 593 (6.8) 110 (6.8) 0.43
 Vasculitis 77 (0.74) 63 (0.72) 14 (0.87) 0.26
 GIT 1059 (10.2) 860 (9.8) 199 (12.3) 0.8
 CVS 619 (6) 501 (5.73) 118 (7.3) 0.14
 Chest 732 (7.1) 605 (6.9) 127 (7.9) 0.07
 FMS 760 (7.3) 713 (8.1) 47 (2.9)  < 0.0001
 Renal 205 (2) 137 (1.6) 68 (4.2)  < 0.0001
Laboratory investigations
 Hemoglobin (g/dl) 11.6 ± 1.5 11.5 ± 1.4 12.3 ± 1.7  < 0.0001
 TLC (× 103/mm3) 7.1 ± 2.5 7 ± 2.5 7.3 ± 2.5  < 0.0001
 Platelets (× 103/mm3) 297.1 ± 95.2 297.7 ± 94.8 293.1 ± 98.2 0.18
 ESR (mm/1st hr) 45 ± 27.7 45 ± 27.5 45.1 ± 28.7 0.85
 CRP (mg/dl) 17.5 ± 22.6 16.9 ± 21.9 22.6 ± 26.4 0.036
 ALT (IU/l) 21.7 ± 15.3 21.8 ± 15.2 21.1 ± 16 0.22
 AST (IU/l) 22.6 ± 15.7 22.8 ± 15.7 21.3 ± 15.7 0.02
 Urea (mg/dl) 19.5 ± 17.6 19.9 ± 17.6 17.5 ± 17.1 0.009
 Creatinine (mg/dl) 0.71 ± 0.34 0.71 ± 0.32 0.76 ± 0.45 0.001
 Cholesterol (mg/dl) 195.4 ± 62.4 193.1 ± 56.8 206 ± 87.9 0.02
 Triglycerides (mg/dl) 123.9 ± 55.5 124.9 ± 53.7 115.8 ± 68.1 0.11
 HDL (mg/dl) 55.4 ± 29.3 55.9 ± 28.8 51.5 ± 32.2 0.09
 LDL (mg/dl) 104.1 ± 40.3 104.8 ± 38.7 98.6 ± 51.1 0.15
 SUA (mg/dl) 4.68 ± 1.4 4.6 ± 1.4 5 ± 1.5  < 0.0001
 RF (n = 7992, F:M 6877/1115) 5889 (73.7) 5022 (73) 867 (77.8)  < 0.0001
 Anti-CCP (n = 5433,F:M 4617/816) 3623 (66.7) 3046 (66) 577 (70.7) 0.007
 ANA (n = 2556, F:M 2271/285) 330 (12.9) 302 (13.3) 28 (9.8) 0.07
HAQ 0.95 ± 0.64 0.95 ± 0.63 0.97 ± 0.7 0.56
DAS28 4.43 ± 1.44 4.4 ± 1.4 4.3 ± 1.6 0.015
Open in a new tab

Statistical analysis was done using a Chi-square or Mann Whitney U tests. Bold values are significant at p < 0.05

BMI body mass index, HCV hepatitis C virus, hx history, CNS central nervous system, GIT gastrointestinal tract, CVS cardio-vascular system, FMS fibromyalgia syndrome, TLC total leucocytic count, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, HDL high density lipoprotein. LDL low density lipoprotein, SUA serum uric acid, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide, ANA antinuclear antibody, HAQ health assessment questionnaire, DAS28 disease activity score

Certain variables according to the geo-location are presented in Table 2 and graphically presented in Figs. 1 and 2. The age at onset, gender distribution, disease activity, RF and anti-CCP positivity were significantly varied. The least age at onset, F:M, RF and anti-CCP positivity were present in Upper Egypt, while the highest DAS28 was reported in Canal cities and Sinai. The HAQ was significantly increased in Upper Egypt with the least disability in Canal cities and Sinai. Biological therapy intake was higher in Lower Egypt (46.3%), followed by the Capital (33.1%), Upper Egypt (20.3%) and the Canal cities and Sinai (0.2%) (p < 0.0001).

Table 2.

Age at onset, gender, disease activity, rheumatoid factor and anti-cyclic citrullinated peptide in rheumatoid arthritis patients according to the geo-location

Geo-location Total
(n = 10,364)		 Age at onset
(years)		 F:M DAS28 Positive
RF		 Positive
anti-CCP

Lower Egypt

Delta and N Coast

 1802 40.4 ± 10.8 4.73:1 4.43 ± 1.3 1204/1502 (80.2) 926/1270 (72.9)
1 Alexandria 235 35.8 ± 9.6 8.4:1 5.02 ± 1.5 88/137 (64.2) 140/189 (74.1)
2 Beheira 15 40.5 ± 9.3 4:1 4.01 ± 1.6 11/15 (73.3) 3/5 (60)
3 Kafr El-Sheikh 298 37 ± 11 4.6:1 4.8 ± 1.4 148/223 (66.4) 67/99 (67.7)
4 Damietta 59 45.2 ± 12.4 18.7:1 4.7 ± 1.2 47/59 (79.7) 13/25 (52)
5 Gharbia 558 46.4 ± 6.8 3.5:1 3.7 ± 0.82 454/513 (88.5) 469/499 (94)
6 Dakahlia 389 37 ± 11.3 4.9:1 4.6 ± 1.5 263/320 (82.2) 171/263 (65)
7 Sharkia 60 39.2 ± 10.6 7.6:1 4 ± 1.8 38/47 (80.6) 8/12 (66.7)
8 Menoufiya 53 44.8 ± 9.2 9.6:1 4.8 ± 1.1 40/53 (75.5) 30/46 (65.2)
9 Kalyoubia 135 37.5 ± 12.1 3.5:1 4.4 ± 1.03 116/135 (85.9) 25/133 (18.8)

Canal cities

and Sinai

 320 40.5 ± 11 5.27:1 4.97 ± 1.4 243/282 (86.2) 200/273 (73.4)
10 Port-Said 6 41.8 ± 10.7 females 4.6 ± 0.14 5/5 (100) 1/2 (50)
11 Ismailia 312 40.4 ± 10.9 5.2:1 5 ± 1.4 237/275 (86.2) 199/270 (73.7)
12 South Sinai 2 48.5 ± 30.4 1:1 4 1/2 (50) 0/1
13 Capital (Cairo) 4812 37.9 ± 11.8 7.8:1 4.38 ± 1.4 3015/4039 (74.6) 1498/2079 (72.1)
Upper Egypt 3430 37.8 ± 11.4 3.9:1 4.4 ± 1.5 1426/2169 (65.7) 999/1808 (55.3)
14 Fayoum 378 40.7 ± 11.9 5.4:1 5 ± 1.2 273/365 (74.8) 250/316 (79.1)
15 Beni-Suef 433 38 ± 11.4 3.4:1 4.9 ± 1.7 240/397 (60.5) 184/313 (58.8)
16 Minia 518 36.8 ± 10.7 4.6:1 3.7 ± 1.4 322/516 (62.4) 227/468 (48.5)
17 Assiut 823 37.7 ± 11.4 4.9:1 4.7 ± 1.5 449/706 (63.6) 260/597 (43.6)
18 Sohag 1132 37 ± 11.6 3:1 4.2 ± 1.6 35/55 (63.6) 8/16 (50)
19 Qena 42 42.7 ± 11.04 9.5:1 4.2 ± 0.97 20/30 (66.7) 7/15 (46.7)
20 Aswan 98 39.2 ± 9.4 3.9:1 4.2 ± 0.97 81/94 (86.2) 62/83 (74.7)
21 Red Sea 2 46.5 ± 7.8 Females 5.7 ± 1.1 2/2 (100) –
22 New Valley 4 43.3 ± 11.1 Females NA 4/4 (100) 1/2 (50)
p  < 0.0001  < 0.0001  < 0.0001  < 0.0001  < 0.0001
Open in a new tab

Statistical analysis was done using analysis of variance (ANOVA) tests. Bold values are significant at p < 0.05

F:M female to male ratio, DAS28 disease activity score, RF rheumatoid factor, ACPA: anti-cyclic citrullinated peptide

Fig. 1.

Fig. 1

Open in a new tab

Rheumatoid factor and anti-cyclic citrullinated peptide (anti-CCP) in rheumatoid arthritis patients across different geographic regions in Egypt. LE lower Egypt, C and S Canal and Sinai, UE Upper Egypt. Statistical analysis was done using analysis of variance (ANOVA) tests

Fig. 2.

Fig. 2

Open in a new tab

The age at onset, gender distribution, disease activity, rheumatoid factor and anti-cyclic citrullinated peptide positivity as well as the main medications received by rheumatoid arthritis patients from the four main regions across Egypt. Lower Egypt (North coast and Delta); ALX: Alexandria, BH: Beheira, KS: Kafr El Sheikh, DM: Damietta, GB: Gharbia, DK: Dakahlia, SK: Sharkia, MNF: Menoufiya, KB: Kalyoubia. Canal cities and Sinai; PS: Port-Said, IS: Ismailia, SZ: Suez. Upper Egypt; FM: Fayoum, BS: Beni-Suef, MN: Minia, AST: Assuit, SO: Sohag, QN: Qena, LX: Luxor, ASW: Aswan. HCQ: hydroxychloroquine, MTX: methotrexate, LFN: leflunomide

Discussion

This cross-sectional study presented the socio-demographic, clinical, and therapeutic profile of 10,364 RA patients recruited across Egypt. In the present work the mean age at onset of RA patients in Egypt was 38 years which was significantly lower in females. The F:M was 5.4:1. The age at onset, gender distribution and disease characteristics of RA patients in countries from different continents were compared to the current study (Table 3). Interestingly, the age at onset was lower than that in other countries and nations [10–15] while it was comparable with that from Arab countries [16] and Turkey [17]. A potential explanation could be related to the lower average age of the populations in the Middle Eastern countries [18]. However, genetic and environmental factors cannot be excluded. The higher F:M was comparable to large registries from Latin America [13, 19, 20] thus raising the subject about an increasing shift in the ratio. Once more, the BMI in the RA patients of the current study were similar to that reported from Turkey [17]. RA, the most common inflammatory rheumatic disease, is no exception, with a F:M > 4 before 50 years old and < 2 after the age of 60 [21]. Furthermore, with the increasing incidence of spondyloarthritis (SpA) worldwide, it could have been that more male patients were misdiagnosed as having RA.

Table 3.

The age at onset, gender distribution and disease characteristics of the rheumatoid arthritis patients in countries from different continents compared to the current study

Parameter Europe USA Latin Asia ECR
[10] [11] [5, 12] [13, 20] [19] [29] [17] [14, 15]
no 14,438 3898 42,000 81,386 3717 4721 1038 30,501 10,364
Countries UK

EU

Canada

 USA Colombia

Brazil

Argentina

 South Korea Turkey China Egypt
graphic file with name 296_2022_5258_Figa_HTML.gif

graphic file with name 296_2022_5258_Figb_HTML.gif

graphic file with name 296_2022_5258_Figc_HTML.gif

 graphic file with name 296_2022_5258_Figd_HTML.gif graphic file with name 296_2022_5258_Fige_HTML.gif

graphic file with name 296_2022_5258_Figf_HTML.gif

graphic file with name 296_2022_5258_Figg_HTML.gif

 graphic file with name 296_2022_5258_Figh_HTML.gif graphic file with name 296_2022_5258_Figi_HTML.gif graphic file with name 296_2022_5258_Figj_HTML.gif graphic file with name 296_2022_5258_Figk_HTML.gif
Centres 18 9 registries 83

39

regions

 81 23 36

500 + 

26 regions

 26

Age at

onset (ys)

 ≈ 43 ≈45.1 ≈47 ≈49 ≈44

43.9

 ± 13

41.4

 ± 13.5

 ≈48.6

38.4

 ± 11.6
F:M 3.2:1 4.1:1 3.5:1 5.3:1 5.7:1 5.8:1 4.2:1 4.1:1 5.4:1
Smoking 21.8% 17.6% 12% 11% 8.01% 16.8% 8.2%
DAS28

6.5

 ± 1

4.1

 ± 1

3.5

 ± 1.6

2.4

(1.8–3.3)

4.9

 ± 2.7

46.9%

(3.2–5.1)

3.7

 ± 1.6

5.1

 ± 1.7

4.4

 ± 1.4
RF – 42.5% 75% 76% 92% 86.8% 83.6% 73.7%
ACPA – 32.7% 24% 83.9% 66.7%
MTX 56.6% – – – 84.4% 81.4% 64.4% 55.9% 78%
cDMARDs 65.1% 30.3% 97.5% 90.8% 89.7%
Steroids 50.3% 38% 19% 56.7% 74% 50.4% 40.6% 71.3%
Biologics 100% 100% 100% 15.5% 69.7% 5.8% 10.5% 8.3% 11.6%
Open in a new tab

UK United Kingdom, EU Europe, USA United States of America, FM female to male, DAS28 disease activity score, RF rheumatoid factor, ACPA anti-citrullinated peptide antibody, MTX methotrexate, cDMARDs disease modifying anti-rheumatic drugs

The misdiagnosis of SpA as RA leads to a delayed SpA diagnosis and inadequate therapeutic outcomes. Typical SpA-related clinical manifestations were present in RA patients. The advancements and accessibility of imaging modalities pave way for a more precise classification [12]. In this work, associated bronchial asthma and thyroid dysfunction, a family history of RA, Sjögren's syndrome, fibromyalgia syndrome and disease activity were significantly increased in females. It is notable that a lower frequency of females was receiving biologic therapy. On the contrary, males were significantly more smoking, had more renal manifestations, higher serum uric acid, more frequent positivity of RF and anti-CCP. Regarding the various clinical manifestations reported in this work, they were further compared to those from other countries.

Interstitial lung disease (ILD) is a well-known potentially life-threatening complication in RA [22]. The enduring appraisal of the complex relationships between smoking, COPD, and other factors in RA-associated ILD is important [23]. In this work, the reported frequency of smoking in RA patients was lower (8.2%) than that from other studies from the UK (21.8%) [10], European Union (EU) and Canada (17.6%)[11] as well as Turkey (16.8%) [17].

In this work, neurological manifestations were reported at a low frequency. The frequencies of depression and anxiety were doubled in early RA than in long-standing disease. RA patients with short disease duration and functional limitation were more likely to suffer from depression and anxiety [24].

In this study, the reported frequency of cardiovascular manifestations was low. However, there is a considerable rise in mortality and morbidity in RA due to cardiovascular disease (CVD). The augmented risk for heart disease is related to disease activity and chronic inflammation with traditional risk factors and RA-related characteristics playing a central role [25]. RA patients had higher rates of obesity than the general population and this was strongly associated with physical dysfunction [26]. The BMI in this work was higher than that reported from other nations such as the UK [10] and EU [11]. Compared to osteoarthritis (OA), RA patients were significantly more frequently diabetic and smokers but had lower prevalence of obesity and dyslipidemia [27]. The frequency of metabolic syndrome in RA patients is doubled and raises the risks of stroke and heart disease [28]. The frequency of diabetes mellitus in this work was similar to the USA [12] and Latin American [19] registries, CVD was comparable to the USA CORRONA study [12] and chest involvement was in line to the Korean registry (KORRONA)[29].

In this work, the RF was positive in 73.7% while the anti-CCP was positive in 66.7%. The frequency of RF was comparable to that from a large Colombian study on 68,247 cases [13] and to the CORONNA study from USA [12]. It was lower than Asian studies from Korea (86.8%)[29] and China (84.7%)[14]. Moreover, the frequency of anti-CCP positivity was lower than that reported in a Korean work (83.9%)[29] but higher than the registries from Colombia (24%)[13] and from the EU (32.7%)[11]. Anti-CCP and RF combined detection improves the diagnostic efficiency of RA, providing a potential strategy for early clinical screening [30]. The frequency of remission is three times higher in sero-negative patients with RA. However, the rate of remission does not depend on the serological status as almost two thirds of patients achieve remission in the first 6 months of DMARDs therapy. Anti-CCP and RF titers at the onset of the disease do not influence remission [31].

There was moderate disability in the present cases as measured by the HAQ. The functional capacity (physical and psychosocial) is a central treatment aspect to consider when the RA therapeutic strategy is personalized [32]. The average HAQ score reported in a population-based study was 0.49, and in RA was 1.2 [9]. The disease activity score in the present work was similar to that reported from the EU [11], higher than that from Turkey [17] and the USA [12] while it was lower than that from the UK [10] and China [14].

The medications received by the patients of the current study were diverse. In this study, more males were receiving HCQ and biologic therapy and with a lower disease activity. In early RA, targets can be achieved when the baseline level of diseases activity is low, with male gender and shorter disease duration [33]. In this work, MTX was received by 77.9%. Using MTX before initiating biologic therapy may contribute to a cost-effective RA care [34]. Variables related to MTX failure such as female gender, higher BMI, smoking, higher disease activity and diabetes can aid in predicting the disease process and outcome of treatment [35]. 54.8% of cases received leflunomide while 37.1% received sulfasalazine. Leflunomide is comparable to sulfasalazine in MTX-failed RA patients with similar safety profile [36]. 11.6% of the current patients were on biologics while in Korea a 6 times fold usage was reported [37].

Across the country there was a significant difference in the age at onset, gender distribution, disease activity, RF and anti-CCP positivity. A potential converse causal link between educational accomplishment and the risk of RA has been noticed [38].

National Registries are essential to direct current practice. RA registries in the Middle East and North Africa (MENA) region are rarely presented [39]. On comparing the findings to countries from other continents, variations were easily noted.

In a study from Morocco on 225 RA cases, the age of onset (44 years), F:M (7.1:1), DAS28 (5.2 ± 1), RF positivity (90.5%), anti-CCP positivity (88.8%) were higher than the current findings however, those patients were all receiving biologic therapy [40].

In a study on 300 RA patients from Palestine, treatment with biologic therapy, younger age, having work, higher income, absence of morning stiffness and absence of co-morbidities were significantly associated with better quality of life and less disability [41]. In the work from a tertiary care hospital in KSA on 288 RA patients, the majority (88%) were females with a F:M 7.3:1. In agreement to this work, hypertension was the most common co-morbidity followed by diabetes and almost all of their patients had high disease activity at presentation time [42]. Compared to patients in Western countries, South Korean patients with RA, even those with better physical function, seem to have a lower quality of life [43]. In a study conducted by the Korean College of Rheumatology (KCR) on 2422 patients with a F:M 6.8:1, 19.4% were overweight and 16.1% obese, 13.6% smoked, 11.6% had dyslipidemia, 28% were hypertensive and 4.5% were diabetic. RF and anti-CCP were positive in 82.6% and 86.9%, respectively. The mean DAS28 was 4.7 ± 1.6, 79.9% were receiving steroids, 93.2% MTX, 68.8% HCQ and 46.3% LFN while 61.7% were on biologics [37].

In a large RA registry in the UK, of 27,607 patients, 70.6% were female (F:M 2.4:1) and their mean BMI was 27.3 [44]. In a study from 11 registries from 9 European countries: France, Sweden, Czech, UK, Denmark, Italy, Germany and Portugal on 130,315 RA patients; for biologic naive patients the age at onset was 56.4 years and F:M 2.6:1 and for those who received anti-TNF the age at onset was 46.5 years and F:M was 3:1 [45].

In a large nationwide US study, the F:M was 2.4:1. Obesity was present in 15.1%, diabetes in 20.4% and dyslipidemia in 48% [46].

Although this is currently the largest data of RA patients from across Egypt, there is a desperate need for effective and applicable national management strategies and guidelines. It seems that still across the country the diagnostic tests are not strictly considered for all patients. In spite that the medications received are mostly alike among the major cities, there is a disperse intake of biologic therapy being higher along a North to South gradient.

In conclusion, the spectrum of RA phenotype in Egypt is variable across the country with an increasing shift in the F:M ratio. The age at onset was lower than in other countries.

Acknowledgements

Collaborators of the Egyptian College of Rheumatology: Gehad Elsehrawy, https://orcid.org/0000-0002-1447-0543, Rheumatology Department, Faculty of Medicine, Suez-Canal University, Ismailia, Egypt. Soha Senara, https://orcid.org/0000-0001-7495-8535, Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt. Safaa Sayed, https://orcid.org/0000-0003-4571-6638, Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Saad M Elzokm, https://orcid.org/0000-0002-0623-6132. Rheumatology Department, Faculty of Medicine, Al-Azhar University, Damiette, Egypt. Emad El-Shebini, https://orcid.org/0000-0002-9607-747X, Internal Medicine Department, Rheumatology Unit, Menoufia University, Menoufia, Egypt. Dina H El-Hammady, https://orcid.org/0000-0001-5962-8255, Rheumatology Department, Faculty of Medicine, Helwan University, Cairo, Egypt. Ahmed Y Ismail, https://orcid.org/0000-0002-8161-4666, Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt. Wael Abdel Mohsen, https://orcid.org/0000-0001-6568-9847, Rheumatology Department, Faculty of Medicine, South Valley University, Qena, Egypt. Reem H Mohammed, https://orcid.org/0000-0003-4994-7687, Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Hatem H El-Eishi, https://orcid.org/0000-0002-6365-8024, Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. Othman Hammam, https://orcid.org/0000-0002-5195-5136, Assiut University Hospitals, Assiut University, Assiut Egypt.

Author contributions

All co-authors contributed in line with the ICMJE 4 authorship criteria and take full responsibility for the integrity and accuracy of all aspects of the work. All co-authors take full responsibility for the integrity and accuracy of all aspects of the work.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Data availability

Data are available upon request.

Declarations

Conflict of interest

None.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Chauhan K, Jandu JS, Goyal A, Bansal P, Al-Dhahir MA. StatPearls [Internet] Treasure Island (FL): Stat Pearls Publishing; 2021. Rheumatoid arthritis. [Google Scholar]
  • 2.Kondo N, Kuroda T, Kobayashi D. Cytokine networks in the pathogenesis of rheumatoid arthritis. Int J Mol Sci. 2021;22(20):10922. doi: 10.3390/ijms222010922. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sokolova MV, Schett G, Steffen U. Autoantibodies in rheumatoid arthritis: historical background and novel findings. Clin Rev Allergy Immunol. 2022;63(2):138–151. doi: 10.1007/s12016-021-08890-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Salaffi F, Di Carlo M, Farah S, Marotto D, Atzeni F, Sarzi-Puttini P. Rheumatoid arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. Acta Biomed. 2021;92(4):e2021238. doi: 10.23750/abm.v92i4.10831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Curtis JR, Jain A, Askling J, Bridges SL, Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40(1):2–14.e1. doi: 10.1016/j.semarthrit.2010.03.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Heutz J, de Jong PHP. Possibilities for personalised medicine in rheumatoid arthritis: hype or hope. RMD Open. 2021;7(3):e001653. doi: 10.1136/rmdopen-2021-001653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology/ European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi: 10.1002/art.27584. [DOI] [PubMed] [Google Scholar]
  • 8.Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48. doi: 10.1002/art.1780380107. [DOI] [PubMed] [Google Scholar]
  • 9.Bruce B, Fries JF. The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1:20. doi: 10.1186/1477-7525-1-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 2019;58(12):2162–2169. doi: 10.1093/rheumatology/kez188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Courvoisier DS, Alpizar-Rodriguez D, Gottenberg JE, Hernandez MV, Iannone F, Lie E, et al. Rheumatoid arthritis patients after initiation of a new biologic agent: trajectories of disease activity in a large multinational cohort study. EBioMedicine. 2016;11:302–306. doi: 10.1016/j.ebiom.2016.08.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Mease PJ, Bhutani MK, Hass S, Yi E, Hur P, Kim N. Comparison of clinical manifestations in rheumatoid arthritis vs. spondyloarthritis: a systematic literature review. Rheumatol Ther. 2022;9(2):331–378. doi: 10.1007/s40744-021-00407-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Santos-Moreno P, Castillo P, Villareal L, Pineda C, Sandoval H, Valencia O. Clinical outcomes of patients with rheumatoid arthritis treated in a disease management program: real-world results. Open Access Rheumatol. 2020;12:249–256. doi: 10.2147/OARRR.S270700. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Song X, Wang YH, Li MT, Duan XW, Li HB, Zeng XF, Co-authors of CREDIT Chinese registry of rheumatoid arthritis: IV. Correlation and consistency of rheumatoid arthritis disease activity indices in China. Chin Med J (Engl) 2021;134(12):1465–1470. doi: 10.1097/CM9.0000000000001517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jin S, Li M, Fang Y, Li Q, Liu J, CREDIT Co-authors Chinese registry of rheumatoid arthritis (CREDIT): II. Prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):251. doi: 10.1186/s13075-017-1457-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dargham SR, Zahirovic S, Hammoudeh M, Al Emadi S, Masri BK, Halabi H, et al. Epidemiology and treatment patterns of rheumatoid arthritis in a large cohort of Arab patients. PLoS ONE. 2018;13(12):e0208240. doi: 10.1371/journal.pone.0208240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ayhan FF, Ataman Ş, Rezvani A, Paker N, Taştekin N, Kaya T, et al. Obesity associated with active, but preserved joints in rheumatoid arthritis: results from our national registry. Arch Rheumatol. 2016;31(3):272–280. doi: 10.5606/ArchRheumatol.2016.5761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Youth UNPo (2011) Regional overview: youth in the Arab region
  • 19.Ranza R, de la Vega MC, Laurindo IMM, Gómez MG, Titton DC, Kakehasi AM, et al. Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR. Clin Rheumatol. 2019;38(8):2129–2139. doi: 10.1007/s10067-019-04516-2. [DOI] [PubMed] [Google Scholar]
  • 20.Castillo-Cañón JC, Trujillo-Cáceres SJ, Bautista-Molano W, Valbuena-García AM, Fernández-Ávila DG, Acuña-Merchán L. Rheumatoid arthritis in Colombia: a clinical profile and prevalence from a national registry. Clin Rheumatol. 2021;40(9):3565–3573. doi: 10.1007/s10067-021-05710-x. [DOI] [PubMed] [Google Scholar]
  • 21.Alpízar-Rodríguez D, Pluchino N, Canny G, Gabay C, Finckh A. The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology. 2017;56(8):1254–1263. doi: 10.1093/rheumatology/kew318. [DOI] [PubMed] [Google Scholar]
  • 22.Qiu M, Jiang J, Nian X, Wang Y, Yu P, Song J, et al. Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis. Respir Res. 2021;22(1):264. doi: 10.1186/s12931-021-01856-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zheng B, de Soares MC, Machado M, Pineau CA, Curtis JR, Vinet E, Bernatsky S. Association between chronic obstructive pulmonary disease, smoking, and interstitial lung disease onset in rheumatoid arthritis. Clin Exp Rheumatol. 2022;40(7):1280–1284. doi: 10.55563/clinexprheumatol/i9au1r. [DOI] [PubMed] [Google Scholar]
  • 24.Geng Y, Gao T, Zhang X, Wang Y, Zhang Z. The association between disease duration and mood disorders in rheumatoid arthritis patients. Clin Rheumatol. 2022;41(3):661–668. doi: 10.1007/s10067-021-05967-2. [DOI] [PubMed] [Google Scholar]
  • 25.Rezuș E, Macovei LA, Burlui AM, Cardoneanu A, Rezuș C. Ischemic heart disease and rheumatoid arthritis-two conditions, the same background. Life (Basel) 2021;11(10):1042. doi: 10.3390/life11101042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Baker JF, Giles JT, Weber D, George MD, Leonard MB, Zemel BS, et al. Sarcopenic obesity in rheumatoid arthritis: prevalence and impact on physical functioning. Rheumatology (Oxford) 2021 doi: 10.1093/rheumatology/keab710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Cacciapaglia F, Spinelli FR, Piga M, Erre GL, Sakellariou G, Manfredi A, et al. Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the cardiovascular obesity and rheumatic disease (CORDIS) study group. Eur J Intern Med. 2022;96:60–65. doi: 10.1016/j.ejim.2021.10.001. [DOI] [PubMed] [Google Scholar]
  • 28.Hee JY, Protani MM, Koh ET, Leong KP, Seng TT, Hospital Rheumatoid Arthritis Study Group Metabolic syndrome and its effect on the outcomes of rheumatoid arthritis in a multi-ethnic cohort in Singapore. Clin Rheumatol. 2022;41(3):649–660. doi: 10.1007/s10067-021-05945-8. [DOI] [PubMed] [Google Scholar]
  • 29.Sung YK, Cho SK, Choi CB, Park SY, Shim J, Ahn JK, et al. Korean observational study network for arthritis (KORONA): establishment of a prospective multicenter cohort for rheumatoid arthritis in South Korea. Semin Arthritis Rheum. 2012;41(6):745–751. doi: 10.1016/j.semarthrit.2011.09.007. [DOI] [PubMed] [Google Scholar]
  • 30.Yang X, Cai Y, Xue B, Zhang B. Diagnostic value of anti-cyclic citrullinated peptide antibody combined with rheumatoid factor in rheumatoid arthritis in Asia: a meta-analysis. J Int Med Res. 2021;49(9):3000605211047714. doi: 10.1177/03000605211047714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Iaremenko O, Mykytenko G. Achievement of clinical remission in patients with rheumatoid arthritis depending on the ACCP-and RF-serological status. Georgian Med News. 2021;318:99–104. [PubMed] [Google Scholar]
  • 32.Bywall KS, Esbensen BA, Lason M, Heidenvall M, Erlandsson I, Johansson JV. Functional capacity vs side effects: treatment attributes to consider when individualising treatment for patients with rheumatoid arthritis. Clin Rheumatol. 2022;41(3):695–704. doi: 10.1007/s10067-021-05961-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Capelusnik D, Aletaha D. Baseline predictors of different types of treatment success in rheumatoid arthritis. Ann Rheum Dis. 2022;81(2):153–158. doi: 10.1136/annrheumdis-2021-220853. [DOI] [PubMed] [Google Scholar]
  • 34.Pardey N, Zeidler J, Nellenschulte TF, Stahmeyer JT, Hoeper K, Witte T. Methotrexate treatment before use of biologics in rheumatoid arthritis: analysis of guideline compliance. Z Rheumatol. 2021 doi: 10.1007/s00393-021-01086-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Siddiqui A, Totonchian A, Ali JB, Ahmad I, Kumar J, Shiwlani S, et al. Risk factors associated with non-respondence to methotrexate in rheumatoid arthritis patients. Cureus. 2021;13(9):e18112. doi: 10.7759/cureus.18112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Belani PJ, Kavadichanda CG, Negi VS. Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial. Rheumatol Int. 2022;42(5):771–782. doi: 10.1007/s00296-021-04994-1. [DOI] [PubMed] [Google Scholar]
  • 37.Kim SK, Kwak SG, Choe JY. Association between biologic disease modifying anti-rheumatic drugs and incident hypertension in patients with rheumatoid arthritis: results from prospective nationwide KOBIO registry. Medicine (Baltimore) 2020;99(9):e19415. doi: 10.1097/MD.0000000000019415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Huang G, Cai J, Li W, Zhong Y, Liao W, Wu P. Causal relationship between educational attainment and the risk of rheumatoid arthritis: a Mendelian randomization study. BMC Rheumatol. 2021;5(1):47. doi: 10.1186/s41927-021-00216-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Almoallim H, Hassan R, Cheikh M, Faruqui H, Alquraa R, Eissa A, et al. Rheumatoid arthritis Saudi database (RASD): disease characteristics and remission rates in a tertiary care center. Open Access Rheumatol. 2020;12:139–145. doi: 10.2147/OARRR.S260426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Eddaoudi M, Rostom S, Hmamouchi I, Binoune IE, Amine B, Abouqal R, et al. The first biological choice in patients with rheumatoid arthritis: data from the Moroccan register of biotherapies. Pan Afr Med J. 2021;38:183. doi: 10.11604/pamj.2021.38.183.27081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Al-Jabi SW, Seleit DI, Badran A, Koni A, Zyoud SH. Impact of socio-demographic and clinical characteristics on functional disability and health-related quality of life in patients with rheumatoid arthritis: a cross-sectional study from Palestine. Health Qual Life Outcomes. 2021;19(1):241. doi: 10.1186/s12955-021-01874-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.AlOmair M, AlMalki H, AlShamrani N, Habtar G, AlAsmari M, Mobasher W, et al. Patterns of response to different treatment strategies in seropositive rheumatoid arthritis patients in a tertiary hospital in south-western Saudi Arabia: a retrospective study. Open Access Rheumatol. 2021;13:239–246. doi: 10.2147/OARRR.S322833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Suh CH, Lee K, Kim JW, Boo S. Factors affecting quality of life in patients with rheumatoid arthritis in South Korea: a cross-sectional study. Clin Rheumatol. 2022;41(2):367–375. doi: 10.1007/s10067-021-05944-9. [DOI] [PubMed] [Google Scholar]
  • 44.Hawley S, Edwards CJ, Arden NK, Delmestri A, Cooper C, Judge A, et al. Descriptive epidemiology of hip and knee replacement in rheumatoid arthritis: an analysis of UK electronic medical records. Semin Arthritis Rheum. 2020;50(2):237–244. doi: 10.1016/j.semarthrit.2019.08.008. [DOI] [PubMed] [Google Scholar]
  • 45.Mercer LK, Askling J, Raaschou P, Dixon WG, Dreyer L, Hetland ML, et al. Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Ann Rheum Dis. 2017;76(2):386–391. doi: 10.1136/annrheumdis-2016-209285. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Peterson MN, Dykhoff HJ, Crowson CS, Davis JM, 3rd, Sangaralingham LR, Myasoedova E. Risk of rheumatoid arthritis diagnosis in statin users in a large nationwide US study. Arthritis Res Ther. 2021;23(1):244. doi: 10.1186/s13075-021-02617-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data are available upon request.

Articles from Rheumatology International are provided here courtesy of Springer

RESOURCES